Leadership Expansion at Entrada Therapeutics
Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a vibrant clinical-stage biopharmaceutical company focused on changing patient care through groundbreaking therapies. Recently, the company announced a significant change in its leadership structure. Natarajan Sethuraman, PhD, known for his remarkable dedication and expertise as the Chief Scientific Officer, has now been named the President of Research and Development.
The Influence of Dr. Sethuraman at Entrada
Since the beginning of Entrada Therapeutics, Dr. Sethuraman has been a key player in the company. His time with the firm has been marked by vital contributions that have shaped its research and clinical development efforts. Dipal Doshi, the Chief Executive Officer of Entrada Therapeutics, praised Natarajan's leadership, noting its essential role in the company’s diverse pipeline of proprietary intracellular therapeutics. Natarajan's extensive experience in various therapeutic development stages has been crucial in advancing their ENTR-601-44 program into clinical trials.
Dedication to Innovative Therapeutics
In an inspiring statement, Dr. Sethuraman shared his excitement for the company's mission and the potential behind their innovative approaches to intracellular therapeutics. He sees significant promise in their ability to develop treatments for previously unreachable targets. He's proud of the progress made by his team and looks forward to advancing their clinical pipeline further to improve patients' lives.
Path of Expertise and Leadership
Dr. Sethuraman joined Entrada Therapeutics as Chief Scientific Officer in 2017, where he has successfully directed global research and clinical development projects. His rich background encompasses drug discovery spanning various modalities, including oligonucleotides, antibodies, therapeutic enzymes, and peptides. His leadership has cultivated a strong R&D team committed to advancing a wide range of proprietary programs from concept all the way to clinical stages.
Previous Roles and Academic Achievements
Before making a significant impact at Entrada, Dr. Sethuraman played a crucial role at Merck & Co., Inc. There, he managed the GlycoFi site and directed the research and development of innovative biologics after Merck acquired GlycoFi. He earned his PhD in Entomology, Molecular Biology, and Biochemistry from the Indian Agricultural Research Institute, along with a BSc from Tamil Nadu Agricultural University and post-doctoral training at Duke University.
About Entrada Therapeutics
Entrada Therapeutics is leading the charge in the biopharmaceutical sector by creating a new class of medicines aimed at targeting intracellular mechanisms that were previously thought to be unreachable. Their Endosomal Escape Vehicle (EEV™)-therapeutics ensure effective intracellular delivery of a wide variety of therapeutics throughout different organs and tissues, promising a better therapeutic index. With this unique and modular approach, Entrada is advancing a robust portfolio of RNA, antibody, and enzyme-based therapeutic programs intended to tackle conditions ranging from neuromuscular to immunological diseases.
Advancing Neuromuscular Therapy
In particular, Entrada's primary oligonucleotide programs focus on developing treatments for individuals diagnosed with Duchenne Muscular Dystrophy, utilizing approaches that target exon 44, 45, and 50 skipping. The company has also formed partnerships to advance clinical-stage programs like VX-670, which aim to tackle myotonic dystrophy type 1.
Contact Information
For additional inquiries regarding Entrada Therapeutics, interested individuals can reach out to Karla MacDonald, the Chief Corporate Affairs Officer, via email at kmacdonald@entradatx.com.
Frequently Asked Questions
What is Entrada Therapeutics known for?
Entrada Therapeutics focuses on developing intracellular therapeutics to address conditions that were previously considered untreatable.
Who has been appointed as the new President of Research and Development?
Natarajan Sethuraman, PhD, has been promoted to the position of President of Research and Development at Entrada Therapeutics.
What qualifications does Dr. Sethuraman bring to his position?
Dr. Sethuraman has a wealth of experience in drug discovery and development, including a prior role at Merck, and he has been with Entrada since it was founded.
What areas of therapy does Entrada Therapeutics target?
Entrada Therapeutics is working on treatments for neuromuscular, ocular, metabolic, and immunological diseases, among other conditions.
How can I find more information about Entrada Therapeutics?
For further information, please visit Entrada's official website at www.entradatx.com.
